XML 77 R55.htm IDEA: XBRL DOCUMENT v3.22.4
Fair value of financial instruments and investments - Convertible Notes and Rights Exchange Agreement (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2020
Aug. 15, 2022
Dec. 31, 2021
Apr. 29, 2020
Sep. 30, 2019
Aug. 31, 2015
Financial assets and liabilities measured at fair value on recurring basis              
Payments on deferred consideration obligation $ 40,400,000 $ 38,100,000          
Issuance of common stock related to rights exchange   150,528,000          
Contingent consideration payable 164,000,000     $ 239,900,000      
3.00% Convertible senior notes due 2022 | Convertible debt              
Financial assets and liabilities measured at fair value on recurring basis              
Principal 150,000,000     150,000,000     $ 150,000,000.0
Interest rate ( as a percent )     3.00%       3.00%
1.50% Convertible senior notes due 2026 | Convertible debt              
Financial assets and liabilities measured at fair value on recurring basis              
Principal 287,500,000     287,500,000   $ 287,500,000  
Interest rate ( as a percent )           1.50%  
Significant other observable inputs (Level 2) | 3.00% Convertible senior notes due 2022 | Convertible debt              
Financial assets and liabilities measured at fair value on recurring basis              
Fair value of convertible notes 158,300,000            
Significant other observable inputs (Level 2) | 1.50% Convertible senior notes due 2026 | Convertible debt              
Financial assets and liabilities measured at fair value on recurring basis              
Fair value of convertible notes 281,700,000     305,300,000      
Development and Regulatory Milestones | Recurring basis              
Financial assets and liabilities measured at fair value on recurring basis              
Contingent consideration payable 82,500,000     139,300,000      
Development and Regulatory Milestones | Recurring basis | Significant unobservable inputs (Level 3)              
Financial assets and liabilities measured at fair value on recurring basis              
Contingent consideration payable 82,500,000     139,300,000      
Net Sales Milestones and Royalties | Recurring basis              
Financial assets and liabilities measured at fair value on recurring basis              
Contingent consideration payable 81,500,000     100,600,000      
Net Sales Milestones and Royalties | Recurring basis | Significant unobservable inputs (Level 3)              
Financial assets and liabilities measured at fair value on recurring basis              
Contingent consideration payable $ 81,500,000     100,600,000      
Agilis              
Financial assets and liabilities measured at fair value on recurring basis              
Net sales amount         $ 150,000,000.0    
Agilis | Minimum              
Financial assets and liabilities measured at fair value on recurring basis              
Product sales (as a percent) 2.00%       2.00%    
Agilis | Maximum              
Financial assets and liabilities measured at fair value on recurring basis              
Development milestone payment obligations $ 60,000,000.0            
Priority review voucher amount 535,000,000.0            
Development milestone payment obligations, net of cancellation and forfeiture 20,000,000.0            
Contingent liability, milestone, potential achievements, priority review voucher amount, net of cancellation and forfeiture 361,000,000.0            
Net sales amount $ 150,000,000.0            
Product sales (as a percent) 6.00%       6.00%    
Agilis | Development and Regulatory Milestones | Significant unobservable inputs (Level 3) | Commitments              
Financial assets and liabilities measured at fair value on recurring basis              
Contingent consideration payable- net sales milestones and royalties $ 82,500,000 139,200,000   139,300,000      
Agilis | Net Sales Milestones and Royalties | Significant unobservable inputs (Level 3) | Commitments              
Financial assets and liabilities measured at fair value on recurring basis              
Contingent consideration payable- net sales milestones and royalties 81,500,000 $ 101,200,000   $ 100,600,000      
Non-collaborative Arrangement Transactions | Agilis              
Financial assets and liabilities measured at fair value on recurring basis              
Development milestone payment obligations 40,000,000.0            
Rights Exchange Agreement              
Financial assets and liabilities measured at fair value on recurring basis              
Issuance of common stock related to rights exchange (in shares)   2,821,176          
Issuance of common stock related to rights exchange   $ 150,500,000          
Rights Exchange Agreement | Agilis              
Financial assets and liabilities measured at fair value on recurring basis              
Contingent liability, cancellation and forfeiture $ 211,600,000